checkAd

     154  0 Kommentare Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting - Seite 4

    Zynerba Contact
    Will Roberts, VP Investor Relations and Corporate Communications
    484.581.7489
    robertsw@zynerba.com

    Lesen Sie auch

    Media contact
    Molly Devlin
    Evoke KYNE
    215.928.2199
    Molly.Devlin@evokegroup.com


    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting - Seite 4 DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer